GLPwatch
Ecnoglutide
Pipeline · GLP-1 receptor agonist
Last updated 2026-05-28Ecnoglutide is a GLP-1 receptor agonist, meaning it mimics a natural gut hormone to help regulate blood sugar. It is currently in development and not yet approved for any medical use.
AI summary of the sources below.
| Mechanism | GLP-1 receptor agonist Mimics GLP-1, a gut hormone that raises insulin, lowers blood sugar, and reduces appetite. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | — |
How Ecnoglutide connects
Trials (4)
- XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
- A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
- A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Top research (7)
- Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.
- Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
- Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
- Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
- Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
- Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
- Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.